Generic Name: brentuximab vedotin (bren TUX i mab ve DOE tin)
Brand Name: Adcetris
What is brentuximab vedotin?
Brentuximab vedotin is a cancer medicine that interferes with the growth and spread of cancer cells in the body.
Brentuximab vedotin is used to treat classical Hodgkin lymphoma that could relapse or has already relapsed after a stem cell transplant or treatment with other cancer medications.
Brentuximab vedotin is also used to treat anaplastic large cell lymphoma that affects organs throughout the body (systemic) or that is confined only to the skin (primary cutaneous). Brentuximab vedotin is usually given for these conditions after other treatments have failed.
Brentuximab vedotin was approved for anaplastic large cell lymphoma by the US Food and Drug Administration (FDA) on an "accelerated" basis. In clinical studies, brentuximab vedotin produced complete or partial remission in many people. However, further studies are needed to determine if this medicine can lengthen survival time.
Brentuximab vedotin may also be used for purposes not listed in this medication guide.
You should not receive brentuximab vedotin if you are also receiving another cancer medicine called bleomycin (Blenoxane).
Brentuximab vedotin may cause a serious brain infection that can lead to disability or death. Call your doctor right away if you have any mood or behavior changes, confusion, memory problems, decreased vision, weakness on one side of your body, or problems with speech or walking. These symptoms may start gradually and get worse quickly.
Before taking this medicine
You should not receive brentuximab vedotin if you are allergic to it, or:
if you are also receiving another cancer medicine called bleomycin (Blenoxane).
To make sure brentuximab vedotin is safe for you, tell your doctor if you have:
kidney disease; or
peripheral vascular disease such as Raynaud's syndrome.
Brentuximab vedotin can harm an unborn baby. Do not use this medicine if you are pregnant. Use effective birth control to prevent pregnancy, whether you are a man or a woman. The use of this medicine by either parent may cause birth defects.
Keep using birth control for at least 6 months after your last dose of brentuximab vedotin. Tell your doctor right away if a pregnancy occurs while either the mother or the father is using brentuximab vedotin.
It is not known whether brentuximab vedotin passes into breast milk or if it could harm a nursing baby. You should not breast-feed while you are using brentuximab vedotin.
How is brentuximab vedotin given?
Brentuximab vedotin is injected into a vein through an IV. You will receive this injection in a clinic or hospital setting.
You may be given other medications to help prevent serious side effects or allergic reaction. Keep using these medicines for as long as your doctor has prescribed.
Brentuximab vedotin is usually given once every 3 weeks for up to 16 treatment cycles, or until your body no longer responds to the medication. Follow your doctor's dosing instructions very carefully.
Brentuximab vedotin can lower blood cells that help your body fight infections and help your blood to clot. Your blood will need to be tested often. Your cancer treatments may be delayed based on the results of these tests.
If you need surgery, tell the surgeon ahead of time that you are using brentuximab vedotin. You may need to stop using the medicine for a short time.
What happens if I miss a dose?
Call your doctor if you miss an appointment for your brentuximab vedotin injection.
What happens if I overdose?
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.
What should I avoid while receiving brentuximab vedotin?
Do not receive a "live" vaccine while using brentuximab vedotin. Live vaccines include measles, mumps, rubella (MMR), polio, rotavirus, typhoid, yellow fever, varicella (chickenpox), zoster (shingles), and nasal flu (influenza) vaccine.
Avoid being near people who are sick or have infections. Tell your doctor at once if you develop signs of infection.
This medicine can pass into body fluids (urine, feces, vomit). For at least 48 hours after you receive a dose, avoid allowing your body fluids to come into contact with your hands or other surfaces. Caregivers should wear rubber gloves while cleaning up a patient's body fluids, handling contaminated trash or laundry or changing diapers. Wash hands before and after removing gloves. Wash soiled clothing and linens separately from other laundry.
Brentuximab vedotin side effects
Get emergency medical help if you have signs of an allergic reaction (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning in your eyes, skin pain, red or purple skin rash that spreads and causes blistering and peeling).
Some side effects may occur during the injection or within 24 hours afterward. Tell your caregiver right away if you feel dizzy, nauseated, chilled or feverish, or if you have itching or trouble breathing.
Brentuximab vedotin may cause a serious viral infection of the brain that can lead to disability or death. Call your doctor right away if you have any change in your mental state, decreased vision, weakness on one side of your body, or problems with speech or walking. These symptoms may start gradually and get worse quickly.
Also call your doctor at once if you have any of these other side effects, even if they occur several months after you receive brentuximab vedotin, or after your treatment ends.
numbness, weakness, burning pain, tingly feeling, or loss of feeling in your arms or legs;
sudden chest pain or discomfort, wheezing, dry cough, feeling short of breath;
easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin;
low red blood cells (anemia)--pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet;
signs of infection--fever, chills, mouth or throat pain, skin sores, cough with mucus, pain or burning when you urinate;
signs of tumor cell breakdown--lower back pain, blood in your urine, little or no urinating; numbness or tingly feeling around your mouth; muscle weakness or tightness; fast or slow heart rate, weak pulse, confusion, fainting;
liver or pancreas problems--severe pain in your upper stomach (may spread to your back), nausea and vomiting, tired feeling, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); or
stomach problems--severe constipation, new or worsening stomach pain, bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds.
Common side effects may include:
numbness or tingling in your hands or feet;
trouble moving your hands or feet;
anemia, fever, infections, easy bruising or bleeding;
cold symptoms such as stuffy nose, sneezing, cough, sore throat;
nausea, vomiting, diarrhea;
skin rash; or
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Brentuximab vedotin dosing information
Usual Adult Dose for Hodgkin's Disease:
-Classical Hodgkin lymphoma consolidation: 1.8 mg/kg IV (maximum 180 mg) over 30 minutes every 3 weeks; initiate therapy within 4 to 6 weeks post-auto-HSCT or upon recovery from auto-HSCT; administer every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity
-Relapsed classical Hodgkin lymphoma: 1.8 mg/kg IV (maximum 180 mg) over 30 minutes every 3 weeks; administer every 3 weeks until disease progression or unacceptable toxicity
-Relapsed primary cutaneous anaplastic large cell lymphoma or DC30-expressing mycosis fungoides: 1.8 mg/kg IV (maximum 180 mg) over 30 minutes every 3 weeks; administer every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity
-Relapsed systemic anaplastic large cell lymphoma: 1.8 mg/kg IV (maximum 180 mg) over 30 minutes every 3 weeks; administer every 3 weeks until disease progression or unacceptable toxicity
-The dose for patients weighing greater than 100 kg should be calculated based on a weight of 100 kg.
-Classical HL after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates
-For the treatment of patients with classical HL at high risk of relapse or progression as post-auto-HSCT consolidation
-For treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen
What other drugs will affect brentuximab vedotin?
Many drugs can interact with brentuximab vedotin. Not all possible interactions are listed here. Tell your doctor about all your current medicines and any you start or stop using, especially:
St. John's wort;
an antibiotic or antifungal medicine;
antiviral medicine to treat hepatitis, HIV, or AIDS;
seizure medicine; or
This list is not complete and many other drugs can interact with brentuximab vedotin. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Give a list of all your medicines to any healthcare provider who treats you.
More about brentuximab
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- En Español
- 0 Reviews – Add your own review/rating
- Drug class: CD30 monoclonal antibodies
Other brands: Adcetris
Related treatment guides
Where can I get more information?
- Your doctor or pharmacist can provide more information about brentuximab vedotin.
- Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
- Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 1996-2012 Cerner Multum, Inc. Version: 3.01.
Date modified: January 03, 2018
Last reviewed: November 14, 2017